

Key Information and Investment Disclosure Statement As of July 31, 2024

FUND FACTS

Classification: Equity Feeder Fund NAVPU: USD 99.79 Launch Date: February 1, 2021 Total Fund NAV (Mn): USD 5.37

USD 100.00 **Minimum Investment: Dealing Day:** Daily up to 2:00 PM **Additional Investment:** No minimum **Redemption Settlement:** T+5 End-of-Day

Minimum Holding Period: None **Early Redemption Charge:** None

FEES

Trustee Fees: 0.1273%* **Custodianship Fee: 0.0000%** External Audit Fee: 0.0000%** Other Fees: 0.0138%***

1.50% per annum

BPI Wealth None Isla Lipana Index Licensing Fee

*Monthly rate: Billings received for July 2024 divided by the average daily NAV for the same month valued at USD 5.59 Mn

**Billing is received at the last guarter of the year

***Billings received in July 2024

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the

political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to

limited participants in the market, low trading volumes, market disruptions, among others. Investors are exposed to the risk of loss arising from negative developments in the political, economic and

Country Risk:

social conditions of the focus countries of the underlying securities of the target fund, which may adversely

affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**
- •THIS PRODUCT CANNOT BE SOLD TO YOU UNLESS ITS BENEFITS AND RISKS HAVE BEEN THOROUGHLY EXPLAINED. IF YOU DO NOT FULLY UNDERSTAND THIS PRODUCT, DO NOT PURCHASE OR INVEST IN IT.

FUND PERFORMANCE AND STATISTICS AS OF JULY 31, 2024 (Purely for reference purposes and is not a guarantee of future results) **NAVPU GRAPH** NAVPu over the past 12 months 130 **Highest** 101.86 115 Lowest 79.73 100 **STATISTICS** 85 Volatility, since inception (%) 4 12.97 nchmark Sharpe Ratio 5 70 0.47 Feb-22 Sep-22 May-23 Dec-23 Jul-24 Jun-21 Information Ratio ⁶ -0.27¹ Returns are net of fees. *MSCI World Health Care Index ² Since Inception CUMULATIVE PERFORMANCE (%) 1 ³ Fund performance from Feb to year-end 2021 S.I.² 1 mo 3 mos 6 mos 1YR 3YRS ⁴ Measures the degree to which the Fund fluctuates vis-à-Fund 2.39 7.80 8.53 11.51 -0.60 -0.21 vis its average return over a period of time 13.34 Benchmark 3.27 8.03 8.60 15.01 29.29 ⁵ Used to characterize how well the return of a Fund ANNUALIZED PERFORMANCE (%) 1 compensates the investor for the level of risk taken. The S.I.² 1YR 2YRS 4YRS 5YR 3YRS higher the number, the better. -0.20 -0.06 Fund 11.51 6.81 ⁶ Measures reward-to-risk efficiency of the portfolio Benchmark 8.71 4.77 7.62 13.34 relative to the benchmark. The higher the number, the CALENDAR YEAR PERFORMANCE (%) 1 higher the reward per unit of risk. **YTD** 2023 2022 2021³ Fund 9.00 4.37 -11.52 -0.86 Benchmark 11.52 3.33 -5.02 18.13 PORTFOLIO COMPOSITION *Declaration of Trust is available upon request through **Allocation** % of Fund your branch of account. 98.55 Target Fund **TOP TEN HOLDINGS** Cash and Equivalents 4.48 Name % of Target Fund Others – net of liabilities -3.03 % of Target Fund Eli Lilly & Co 8.30 Regional Breakdown **United States** 70.72 UnitedHealth Grp Inc 7.27 United Kingdom 6.99 5.41 Novo Nordisk A/S 6.78 Denmark AstraZeneca PLC 4.16 Others 15.50 Merck & Co Inc 4.14 Sector Breakdown % of Target Fund Danaher Corp 2.87 Major Pharmaceuticals 24.94 Novartis AG 2.82 Biotechnology 19.98 Bos Scientific Corp 2.39 **Health Services** 15.81 Medical Technology 12.15 Argenx SE 2.23 27.12 Daiichi Sankyo Co 2.13 Others **RELATED PARTY TRANSACTIONS*** The Fund has no transactions and outstanding investments with entities related to BPI Wealth – A Trust Corporation ("BPI Wealth"). * Related party in accordance with BPI Wealth's internal policy. OTHER FUND FACTS **Fund Currency: US** Dollar **Fund structure:** UCITS (IRL)

Benchmark*: MSCI World Health Care Index **Inception Date:** October 31, 2003

Wellington Global Health Care Equity State Street Custodial Services Name of Target Fund: **Custodian:**

(Ireland) Limited

Regulator: Central Bank of Ireland **Total Expense Ratio:** 1.32%

Fund Manager: Wellington Management Company LLP

Fund

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

OUTLOOK AND STRATEGY

Market Review. Global equities posted positive returns in July, with the MSCI All Country World returning 1.6% for the month. In the US, the S&P 500 gained 1.2% after the Consumer Price Index fell to 2.9% in July from 3.0% in June, fueling expectations of a rate cut by the Fed in their September meeting. Economic data appeared mixed with 2Q2024 GDP rising to 2.8% driven by resilient consumer spending, while the labor market cooled down, with nonfarm payrolls decreasing to 114K and the unemployment rate rising to 4.3%. Business activity has also slowed down, with the ISM Manufacturing Index falling to 46.8 from 48.5 in June. On a sector level, 9 of the 11 sectors posted positive results for the month, with communication services and information technology lagged for the period. European equities increased for the month, with the MSCI Europe index returning 2.2% on the back of stable economic data. Eurozone GDP grew by 0.3% in the second quarter, the HCOB Flash Eurozone Composite PMI slightly fell to 50.2 from 50.9 in June, and employment unchanged at 6.4%. Against this backdrop, the European Central Bank left interest rates unchanged with doubt of a rate cut in their September meeting. Japanese markets were negative as the Bank of Japan raised its benchmark interest rate to 0.25% and plans to reduce monthly bond purchases to approximately 3 trillion yen by early 2026 to address yen weakness and support economic growth. Core inflation increased to 2.2% in June, while a tight labor market is expected to drive up wages and boost consumer demand. Emerging market equities increased by 0.3% primarily driven by gains in Europe, Middle East and Africa. In particular, India's upgraded growth forecast bolstered investor sentiment. The MSCI World Health Care returned 3.3% for the month. Within the index, all of the sectors rose over the month. Health care services and biopharma mid cap were the top performing sectors, while biopharma large cap and medical technology were the bottom performing sectors for the month.

Fund Performance. The fund returned 2.39% in July, lagging the benchmark by 88 basis points. Security selection was the primary driver of relative underperformance. Weak selection in biopharma large cap and medical technology was modestly offset by selection in health care services. Sector allocation, a result of our bottom-up stock selection process, contributed to returns. Allocation effect was driven by our out of benchmark allocation to biopharma small cap and overweight to biopharma mid cap.

Fund Strategy. Groundbreaking innovation, supportive valuations and business models positioned to show resilience through the cycle should benefit the sector over the long-term. Within the biopharma industry, breakthrough innovations continue to provide attractive opportunities. We remain selective in large-cap biopharma, avoiding companies with significant patent expirations and risk of future drug pricing pressure. Outside of biopharma, we believe medical technology innovation has never been stronger due to advancements in technology development, engineering capabilities and integrated informatics. Product cycles, procedure recovery, and biopharma innovation are creating investment opportunities. Within health care services, the fund favors companies focused on the societal challenge on improving patient outcomes while reining in costs. The fund will continue to favor companies that develop innovative products designed to address unmet medical needs. Over the long term, the tailwinds of innovation and an aging population should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Wealth is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpiwealth@bpi.com.ph or call us at (632) 8580-2682.

BPI Wealth as Trustee/Investment Manager is regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph